Vatalanib

• UNSPSC Description:

  Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.

• Target Antigen:

  VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vatalanib.html

• Purity:

  99.93

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC=C(C=C1)NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4

• Molecular Weight:

  346.81

• References & Citations:

  [1]Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8|[2]Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596.|[3]Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308.Drug Metab Pharmacokinet. 2017 Jun;32(3):179-188. |J Microbiol Biotechnol. 2015 Aug;25(8):1227-33. |J Pharm Anal. 2023 Sep 11.|Patent. US20170349880A1.|Bioact Mater. 2 January 2022.|Br J Pharmacol. 2019 Sep;176(17):3143-3160. |Evid-Based Compl Alt. 2021 Apr 27.|JCI Insight. 2024 May 22;9(10):e166402.|Kitazato Graduate School of Pharmaceutical Sciences. Kitasato University. 2017.|Oncol Rep. 2016 Mar;35(3):1297-308.|Oxid Med Cell Longev. 18 Jul 2022.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Ulm University. 2023 Mar 21.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  212141-54-3